Prof. Nik Zeps

Professor Zeps has been recently appointed as the inaugural Group Director of Research for Epworth HealthCare in Melbourne, Australia. Prior to that he was the Director of Research at SJG HealthCare from 2012 to 2016 and head of their cancer translational research program from 2008. He is an Adjunct Professor at the Monash University Eastern Clinical School.

He was a member of the Australian Health Ethics Committee from 2006-2012 and the Research Committee of the National Health and Medical Research Council (NHMRC) of Australia from 2009-2015.

Erkko Ylosmaki (PhD)

Erkko Ylösmäki, Senior Scientist, has over 12 years of experience in the development of oncolytic viruses for cancer immunotherapy. During his academic career, he has developed various microRNA-regulated novel oncolytic viruses (both DNA and RNA viruses), for increased safety as well as potency. He has also developed numerous new oncolytic virus-based (e.g. Vaccinia and Herpes Simplex Virus type 1) cancer vaccine platforms that can dramatically enhance CD8+ T cell-specific anti-tumour immunity.

Cambridge Healthtech Institute’s 2nd Annual Oncolytic Virus Immunotherapy Summit

Oncolytic virotherapy represents an exciting new area of cancer treatment which exploits a virus’s ability to selectively replicate and kill tumor tissue while stimulating a patient-specific immune response against cancer. Interest in the field is at an all-time high following several significant deals. However, questions still remain around delivery, product and clinical development, pre-clinical modelling, scale-up, manufacturing and suitable commercial models.

Prof. Vincenzo Cerullo

Prof. Vincenzo Cerullo, Scientific Founder, is a tenure-track associate professor in the Faculty of Pharmacy, Division of Pharmaceutical Biosciences, at the University of Helsinki. He is the group leader at the Immunovirotherapy Lab (IVTLab) at the Centre for Drug Research (CDR). He has extensive experience in the field of immunology research, having received several academic awards for work he completed during both his post-graduate work and extensive research career (over 70 peer reviewed publications).

Petri Priha (Lic.Sc)

Petri Priha, VP of CMC, has over 20 years’ experience in expert and management positions in vaccine, biopharmaceutical protein, and oncolytic adenovirus process development and GMP manufacturing. Prior to joining Valo Therapeutics in January 2017, Petri served as VP of CMC at Targovax, and before that as Director of Process Development and Quality Assurance at Oncos Therapeutics. During his 5 years at Oncos, he was responsible for the CMC development of an oncolytic adenovirus cancer immunotherapy platform.